Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price

Krystal Biotech (NASDAQ:KRYS) had its price target lifted by Citigroup from $206.00 to $215.00 in a research note released on Thursday,Benzinga reports. Citigroup currently has a neutral rating on the stock.

A number of other brokerages have also recently issued reports on KRYS. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday. Finally, Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $187.86 on Thursday. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34. The stock has a market cap of $5.41 billion, a PE ratio of 62.83 and a beta of 0.84. The business’s fifty day moving average is $157.85 and its 200-day moving average is $175.28.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period last year, the firm earned $0.30 EPS. The firm’s revenue for the quarter was up 116.4% on a year-over-year basis. Equities research analysts predict that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in Krystal Biotech during the fourth quarter valued at $95,000. Palisades Investment Partners LLC boosted its position in Krystal Biotech by 9.3% during the fourth quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company’s stock valued at $6,341,000 after purchasing an additional 3,436 shares during the last quarter. Woodline Partners LP boosted its position in Krystal Biotech by 23.0% during the fourth quarter. Woodline Partners LP now owns 221,102 shares of the company’s stock valued at $34,638,000 after purchasing an additional 41,287 shares during the last quarter. Soleus Capital Management L.P. boosted its position in Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock valued at $56,144,000 after purchasing an additional 141,400 shares during the last quarter. Finally, ProShare Advisors LLC boosted its position in Krystal Biotech by 28.6% during the fourth quarter. ProShare Advisors LLC now owns 8,848 shares of the company’s stock valued at $1,386,000 after purchasing an additional 1,967 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).